Achieve Life Sciences, Inc. (ACHV)

In November 2025, the company reported Q3 earnings, which was followed by a share price decline. In March 2026, Achieve Life Sciences reported earnings, leading to a significant share price decrease due to FDA concerns about cytisinicline manufacturing. In April 2026, the stock increased, and the company announced a private placement for up to $354 million and appointed a new CEO. In May 2026, the company is expected to announce its next earnings and hosted a conference call to discuss its first-quarter financial results; the share price increased significantly from the previous year.

The provided search results do not contain explicit information regarding demand seasonality for Achieve Life Sciences, Inc.'s products or services. Demand for cytisinicline is likely driven by public health initiatives, physician prescriptions, and the prevalence of nicotine addiction rather than typical seasonal consumer patterns.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on addressing nicotine dependence by developing and commercializing cytisinicline, a plant-based alkaloid that helps reduce nicotine withdrawal symptoms. If approved, cytisinicline could be the first new FDA-approved treatment option for nicotine dependence in 20 years.

Achieve Life Sciences, Inc. has operational locations in Canada, the United States, and the United Kingdom. The company's headquarters are located in Vancouver, British Columbia, Canada, and Bothell, Washington, USA.

Achieve Life Sciences' reputation has been influenced by both challenges and positive developments in the past year. The company experienced a stock sell-off due to FDA concerns about cytisinicline manufacturing, but it has also received positive analyst coverage. The appointment of a new CEO and the FDA's Breakthrough Therapy Designation for cytisinicline have positively impacted the company's reputation. The company also secured up to $354 million in private placement financing, indicating investor confidence.

Achieve Life Sciences, Inc. has 91 institutional owners and shareholders holding a total of 23,410,489 shares. Tpg GP A LLC is the largest individual shareholder, owning 12.92% of the company. Institutional shareholders own approximately 43.65% of the stock, Achieve Life Sciences insiders own 32.48%, and retail investors own 23.87%.